These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513 [TBL] [Abstract][Full Text] [Related]
12. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Steiner M; Matthes-Martin S; Attarbaschi A; Minkov M; Grois N; Unger E; Holter W; Vormoor J; Wawer A; Ouachee M; Woessmann W; Gadner H Bone Marrow Transplant; 2005 Aug; 36(3):215-25. PubMed ID: 15937510 [TBL] [Abstract][Full Text] [Related]
13. [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation]. Kuroki F; Goto H; Yanagimachi M; Kajiwara R; Fujii H; Isaki S; Takahashi H; Ikuta K; Yokota S Rinsho Ketsueki; 2006 Jul; 47(7):639-44. PubMed ID: 16910574 [TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
15. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995 [TBL] [Abstract][Full Text] [Related]
16. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801 [TBL] [Abstract][Full Text] [Related]
17. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Cooper N; Rao K; Goulden N; Webb D; Amrolia P; Veys P Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S47-50. PubMed ID: 18978744 [TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Cesaro S; Locatelli F; Lanino E; Porta F; Di Maio L; Messina C; Prete A; Ripaldi M; Maximova N; Giorgiani G; Rondelli R; Aricò M; Fagioli F Haematologica; 2008 Nov; 93(11):1694-701. PubMed ID: 18768529 [TBL] [Abstract][Full Text] [Related]
20. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]